Find and Join

• Let’s talk about that Lilly announcement

  There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats. read more →

• Our response to the op-ed in The Hill

  The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO. read more →

• The shortage ends … then what? (Find out at CCH) 

  We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind. read more →

• A new bronze corporate patron

  A big welcome to Ro, APC’s newest tier-level corporate patron! read more →

• Education (and CE) from USP

  For the fourth year in a row, USP will be holding a hybrid live/virtual workshop dedicated to improving the quality of compounding. read more →

• Compounding post-Chevron

  At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.” read more →

• 503B sourcing: our state-by-state analysis

  Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource. read more →

• What we’ll be talking about at CCH

  When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important.  read more →

More News

New resource provides current vs. future comparison

Sure, you know that 503A pharmacies may compound drugs on the FDA shortage list. What you may not know is that the authorization for that comes from an FDA guidance document, not federal law. Preserving that ability in law is one of several substantive provisions of HR 167 (Griffith/Cuellar), APC’s shortage drug legislation now pending in Congress. 

To help illuminate all that HR 167 does, we’ve created this comparison brief.

For instance, the legislation would allow 503A compounding pharmacies to distribute small batches of compounded drugs to hospitals or clinics, including drugs on the FDA Drug Shortage List or the ASHP Drug Shortage List, within some regulatory guardrails. You’ll recall that FDA allowed this for 13 COVID drugs during the pandemic under temporary guidance that has now expired. HR 167 would make that pathway permanent and expand it to other drugs that hospitals are unable to source from a manufacturer or a 503B outsourcing facility. 

“We urge our members to read up on this bill,” said APC’s Savannah Cunningham. “It will be a key priority for Hill visits during Compounders on Capitol Hill – and likely for the remainder of the year and beyond.”